News
SLN
21.30
-0.56%
-0.12
Silence Therapeutics Announces Board Change
TipRanks · 1d ago
Silence Therapeutics Board Veteran Retires
TipRanks · 3d ago
Weekly Report: what happened at SLN last week (0422-0426)?
Weekly Report · 3d ago
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Silence Therapeutics is a biotechnology company focused on discovering and developing novel molecules. The company has an average 12-month price target of $60.57. 7.7 analysts have expressed a variety of opinions on Silence Therapeutic over the past quarter. The average price target for the company is $75.00.
Benzinga · 04/22 18:00
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 04/22 17:39
Weekly Report: what happened at SLN last week (0415-0419)?
Weekly Report · 04/22 09:52
Silence Therapeutics Announces Upcoming AGM
Silence Therapeutics Plc is set to hold its Annual General Meeting (AGM) on May 17, 2024. The meeting can be attended in person in Hoboken, NJ, and virtually via the Lumi Meeting Platform. SLN stock is down 7% in the last week.
TipRanks · 04/16 01:01
Weekly Report: what happened at SLN last week (0408-0412)?
Weekly Report · 04/15 09:49
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
NASDAQ · 04/12 12:21
Silence Therapeutics Announces JAMA Publication Of Additional APOLLO Phase 1 Data For Zerlasiran In Subjects With Elevated Lipoprotein(a)
Zerlasiran is a siRNA designed to lower the body's production of lipoprotein(a), a key genetic risk factor for cardiovascular disease. The study was published in the Journal of the American Medical Association. The company is currently conducting a phase 2 study.
Benzinga · 04/08 15:49
Weekly Report: what happened at SLN last week (0401-0405)?
Weekly Report · 04/08 09:50
Weekly Report: what happened at SLN last week (0325-0329)?
Weekly Report · 04/01 09:50
Weekly Report: what happened at SLN last week (0318-0322)?
Weekly Report · 03/25 09:51
Weekly Report: what happened at SLN last week (0311-0315)?
Weekly Report · 03/18 09:50
Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 17:07
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga · 03/15 16:57
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc reported a loss for 2023. Collaboration revenues were £25.4 million versus £17.501 million a year ago. Chardan Capital and Morgan Stanley raised their price targets on the company's stock. Silence shares fell 3.9% to close at $24.62 on Wednesday.
Benzinga · 03/14 18:01
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 03/14 16:44
Silence Therapeutics Price Target Raised to $45.00/Share From $29.00 by Morgan Stanley
Dow Jones · 03/14 16:44
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $45
Benzinga · 03/14 16:33
More
Webull provides a variety of real-time SLN stock news. You can receive the latest news about Silence Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About SLN
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.